Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
That number is not just large in absolute terms, it is the largest weight-loss signal ever reported in a randomized Phase 3 trial of a GLP-1-class compound, and it arrived with additional secondary findings that reframe what "GLP-1 therapy" could eventually mean: a 75.8% reduction in osteoarthritis pain, a roughly 20% drop in LDL cholesterol, and a 72% reversal rate of prediabetes to normoglycemia in the affected subpopulation
Marketed as Victoza for type 2 diabetes (approved 2010) and Saxenda for chronic weight management (approved 2014), liraglutide paved the way for the current generation of GLP-1 weight loss medications, including its successor semaglutide
It can include grooming, skin care and exercise, but it is also associated with more intensive interventions such as plastic surgery, orthodontics and hair transplants
Commonly reported adverse events in trial reports (non-exhaustive) Gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) reported in controlled trials Decreased appetite Safety monitoring included additional endpoints and clinical assessments per protocol Does retatrutide cause hair loss
Clinical and Safety Outcomes with GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 1 Diabetes: A Real-World Study
It also reduced a secondary kidney composite outcome (sustained 50% eGFR decline, ESKD, or renal death) by 44%
